Abstract
Severe coronavirus disease 2019 (COVID-19) has been associated with certain preexisting health conditions and can cause respiratory failure along with other multi-organ injuries. However, the mechanism of these relationships is unclear, and prognostic biomarkers for the disease and its systemic complications are lacking. This study aims to examine the plasma protein profile of COVID-19 patients and evaluate overlapping protein modules with biomarkers of common comorbidities.
Blood samples were collected from COVID-19 cases (n=307) and negative controls (n=78) among patients with acute respiratory distress. Proteins were measured by proximity extension assay utilizing next-generation sequencing technology. Its associations to COVID-19 disease characteristics were compared to that of preexisting conditions and established biomarkers for myocardial infarction (MI), stroke, hypertension, diabetes, smoking, and chronic kidney disease.
Several proteins were differentially expressed in COVID-19, including multiple pro-inflammatory cytokines such as IFN-γ, CXCL10, and CCL7/MCP-3. Elevated IL-6 was associated with increased severity, while baseline IL1RL1/ST2 levels were associated with a worse prognosis. Network analysis identified several protein modules associated with COVID-19 disease characteristics overlapping with processes of preexisting hypertension and impaired kidney function. BNP and NTpro-BNP, markers for MI and stroke, increased with disease progression and were positively associated with severity. MMP12 was similarly elevated and has been previously linked to smoking and inflammation in emphysema, along with increased cardiovascular disease risk.
In conclusion, this study provides an overview of the systemic effects of COVID-19 and candidate biomarkers for clinical assessment of disease progression and the risk of systemic complications.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Study data was provide by Massachusetts General Hospitalm (MGH) in collaboration with Olink Proteomics.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study was approved and conducted at the Massachusetts General Hospital, and resulting data have already been made publicly available by request.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Study data is available for request as of October 2, 2020.
Abbreviations
- ACE2
- Angiotensin-converting enzyme 2
- ARDS
- Acute respiratory distress syndrome
- BMI
- Body mass index
- CVD
- Cardiovascular-related death
- CKD
- Chronic kidney disease
- COVID-19
- Coronavirus disease 2019
- eGFR
- Estimated glomerular filtration rate
- HF
- Heart failure
- IL-6
- Interleukin-6
- IL1RL1/ST2
- Interleukin 1 receptor-like 1
- LEP
- Leptin
- MERS
- Middle Eastern respiratory syndrome
- MI
- Myocardial infarction
- NGS
- Next-generation sequencing
- NPPB/BNP
- B-type natriuretic peptide
- NPX
- Normalized protein expression
- NT-proBNP
- N-terminal pro–B-type natriuretic peptide
- PEA
- Proximity extension assay
- SARS
- Severe acute respiratory syndrome
- SARS-CoV2
- Severe acute respiratory syndrome coronavirus 2
- WGCNA
- Weighted gene correlation network analysis
